Interferons Drive Lung Cell Aging in COPD — and Blocking Them May Help
New research identifies IFN signaling as a key driver of bronchial epithelial senescence in COPD, pointing to JAK-STAT and cGAS-STING as therapeutic targets.
Summary
Researchers used single-cell RNA sequencing on bronchial epithelial cells from COPD patients and healthy controls to map cellular senescence across airway cell types. They found significantly elevated senescence gene expression — particularly in basal and club cells — along with increased IFN-β and IFN-γ levels. Senescence markers p16 and p21 were elevated in COPD cultures and confirmed in lung tissue biopsies. The senescence-associated secretory phenotype (SASP), which drives chronic inflammation, was also amplified in COPD. Crucially, blocking JAK-STAT signaling with baricitinib or the cGAS-STING pathway with C-176 suppressed both SASP and senescence markers, suggesting these IFN-linked pathways as actionable targets in COPD management.
Detailed Summary
Chronic obstructive pulmonary disease (COPD) is characterized by progressive airway inflammation and tissue dysfunction, yet the cellular mechanisms sustaining this inflammation remain incompletely understood. Cellular senescence — a state of irreversible cell cycle arrest accompanied by a pro-inflammatory secretory program — has been implicated in COPD, but its drivers in the bronchial epithelium were largely unknown. This study set out to identify those drivers and test whether they could be pharmacologically suppressed.
The research team performed single-cell RNA sequencing (scRNA-seq) on well-differentiated primary bronchial epithelial cells derived from COPD patients and healthy control subjects grown at air-liquid interface. This approach allowed high-resolution mapping of senescence gene expression across distinct epithelial cell subtypes. They also assessed protein-level senescence markers, cytokine profiles, and the effects of pathway-specific inhibitors.
The scRNA-seq data revealed a broad upregulation of cellular senescence-associated genes in COPD bronchial epithelium. This pattern was most pronounced in basal and club cells — key progenitor and secretory cell populations critical for airway maintenance and repair. Elevated expression of the canonical senescence markers p16 (CDKN2A) and p21 (CDKN1A) was confirmed at the protein level in COPD cultures and validated histologically in lung tissue sections from COPD patients. Alongside these changes, IFN-β (a Type I interferon) and IFN-γ (a Type II interferon) were both significantly elevated, suggesting that chronic interferon signaling may be a primary inducer of the senescent state in these cells.
Senescence-associated secretory phenotype (SASP) components — pro-inflammatory cytokines and mediators secreted by senescent cells — were also markedly increased in COPD bronchial epithelial cultures. Importantly, treatment with baricitinib (a JAK1/2 inhibitor targeting JAK-STAT signaling downstream of IFN receptors) or C-176 (a covalent STING inhibitor targeting the cGAS-STING innate immune pathway upstream of IFN production) substantially attenuated SASP output and reduced expression of p16 and p21. This bidirectional approach — blocking both IFN production and IFN receptor signaling — demonstrated that interferon pathways are central to maintaining the senescent, pro-inflammatory state in COPD airways.
These findings position IFN-driven senescence as a mechanistic bridge between innate immune activation and the chronic epithelial dysfunction seen in COPD. The ability of existing, clinically approved agents like baricitinib to suppress this axis is particularly significant. While further in vivo validation is needed, these results suggest that senolytics or senomorphic strategies targeting IFN pathways could complement existing COPD therapies by addressing the underlying cellular aging phenotype rather than just downstream inflammation.
Key Findings
- Senescence genes are broadly upregulated in COPD bronchial epithelium, concentrated in basal and club cells.
- Senescence markers p16 and p21 are elevated in COPD cultures and confirmed in patient lung tissue biopsies.
- IFN-β and IFN-γ are significantly increased in COPD bronchial epithelial cells, driving the senescent phenotype.
- SASP inflammatory output is amplified in COPD and suppressed by JAK-STAT inhibitor baricitinib or STING inhibitor C-176.
- Dual IFN pathway inhibition reduces both senescence marker expression and SASP, identifying actionable therapeutic targets.
Methodology
Single-cell RNA sequencing was performed on well-differentiated primary bronchial epithelial cells from COPD patients and healthy controls cultured at air-liquid interface. Senescence markers were validated at protein level by immunostaining and confirmed in human lung tissue biopsies. Pharmacological inhibitors (baricitinib, C-176) were used to probe JAK-STAT and cGAS-STING pathway contributions to senescence and SASP.
Study Limitations
The study relied on in vitro bronchial epithelial cultures and histological tissue sections, without in vivo COPD animal model validation. Patient cohort size for scRNA-seq was not specified in the abstract, and confounders such as smoking history, COPD severity stage, and concurrent medications may influence generalizability. Long-term safety and efficacy of JAK or STING inhibition in the COPD lung context remain untested.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: